Q2 FY2026 · ended Jun 30, 2026 · Revenue $148,000 · Filed Aug 13, 2026
Parabilis Medicines, Inc. (PBLS) files with the SEC under industry code 2834, Pharmaceutical Preparations. In Q2 of fiscal 2026, the quarter ended Jun 30, 2026, it reported revenue of $148,000 and a net loss of $52.5 million. Free cash flow was -$53.8 million. As of Jun 30, 2026 it held $1.1 billion in cash and investments and $53.2 million in total debt.
Revenue
$148,000
Net income
$-52.46M
Operating cash flow
$-52.82M
Free cash flow
$-53.81M
EPS
$-2.32
Dividend per share
None
Shares outstanding
121.94M
Net cash
$1.07B
Q2 FY2026
Operating margin
-34382.4%
Q2 FY2026
Company profile
- Industry
- Pharmaceutical Preparations (SIC 2834)
- Listed as
- PBLS (Nasdaq)
- Fiscal year ends
- December 31
- Incorporated in
- DE
- Headquarters
- Cambridge, MA
- SEC filer status
- , Emerging growth company
- SEC CIK
- 1657677
- Former names
- FOG PHARMACEUTICALS, INC. (until Dec 2, 2022)
Other Pharmaceutical Preparations companies
- ELI LILLY & Co LLY
- Johnson & Johnson JNJ
- AbbVie Inc. ABBV
- Merck & Co., Inc. MRK
- Novartis AG NVS
- Astrazeneca PLC AZN
- Abbott Laboratories ABT
- Novo Nordisk A S NVO
Key figures
Fiscal-year totals from the annual reports; switch to Annual for the full-year view. Balance sheet lines are as of each year end.
| Line | Q2 FY2026 Jun 30, 2026 |
|---|---|
| Revenue | $148,000 |
| Operating income | -$50.9M |
| Net income | -$52.5M |
| Diluted EPS | -$2.32 |
| Operating cash flow | -$52.8M |
| Free cash flow | -$53.8M |
| Total assets | $1.2B |
| Total liabilities | $127.5M |
| Stockholders' equity | $1.0B |
| Cash and investments | $1.1B |
| Total debt | $53.2M |
Recent SEC filings
| Form | Description | Filed | Period |
|---|---|---|---|
| 8-K |
Current report
Material agreement
|
Nov 5, 2026 | Oct 30, 2026 |
| 8-K |
Current report
Regulation FD disclosure
|
Sep 15, 2026 | Sep 15, 2026 |
| 8-K |
Current report
Officer or director change
|
Sep 2, 2026 | Aug 28, 2026 |
| 8-K |
Current report
Officer or director change, Regulation FD disclosure
|
Aug 25, 2026 | Aug 22, 2026 |
| 10-Q | Quarterly report | Aug 13, 2026 | Jun 30, 2026 |
| 8-K |
Current report
Results of operations, Regulation FD disclosure
|
Aug 13, 2026 | Aug 13, 2026 |
All 63 Parabilis Medicines, Inc. SEC filings
Source: SEC EDGAR filings. This is company-reported data, not investment advice.